++
butenafine (byoo-ten-a-feen)
Lotrimin Ultra, Mentax
Classification
Therapeutic: antifungals (topical)
++
Treatment of a variety of cutaneous fungal infections, including tinea pedis (athlete's foot), tinea cruris (jock itch), tinea corporis (ringworm), and tinea versicolor.
++
Affects the synthesis of the fungal cell wall. Therapeutic Effects: Decrease in symptoms of fungal infection.
+++
Adverse Reactions/Side Effects
++
Local: burning, itching, local hypersensitivity reactions, redness, stinging.
+++
PHYSICAL THERAPY IMPLICATIONS
+++
Examination and Evaluation
++
++
Avoid contact with cutaneous lesions when treating patient.
Always wash hands thoroughly and disinfect equipment (whirlpools, electrotherapeutic devices, treatment tables, and so forth) to help prevent the spread of infection.
+++
Patient/Client-Related Instruction
++
Advise patient to report any increased local sensitivity to this drug (pain, burning, itching, swelling).
Instruct patient about proper hygiene, e.g., thoroughly wash and dry the affected area, wear clean socks and ventilated shoes for tinea pedis, and
so forth.
Advise patient to apply the drug as directed for the full course of treatment even if feeling better.
Inform patient that early relief of cutaneous symptoms may be seen in 2–3 days. Full therapeutic response may take 2 wk for tinea cruris, tinea corporis, and tinea versicolor and 4 weeks for tinea pedis.
Advise patient to seek medical help if infections persist or recur after the full treatment. Recurrent fungal infections may be a sign of systemic illness.
++
Absorption: Absorption through intact skin is minimal.
++
Distribution: Distribution after topical administration is primarily local.
++
Metabolism and Excretion: Hepatic via hydroxylation.
++
++
+++
Contraindications/Precautions
++
Contraindicated in: Hypersensitivity to active ingredients, additives, preservatives, or bases; Some products contain alcohol or bisulfites and should be avoided in patients with known intolerance.
++
Use Cautiously in: Nail and scalp infections (may require additional systemic therapy); OB/Lactation: Safety not established.
++
Drug-Drug: None significant.
++
Topical (Adults and Children >12 yr): Apply once daily for 2 wk for patients with tinea corporis, tinea cruris, or tinea versicolor. Apply once daily for 4 wk or twice daily for 7 days for patients with tinea pedis.
++